- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04150848
A Biobehavioral Intervention for Young Men With Testicular Cancer
A Biobehavioral Intervention for Young Men With Testicular Cancer: A Pilot Study
This study is a randomized controlled biobehavioral pilot trial designed to investigate the feasibility and preliminary efficacy of a novel intervention, Goal-focused Emotion-Regulation Therapy (GET) aimed at improving distress symptoms, emotion regulation, goal navigation skills, and stress-sensitive biomarkers in young adult testicular cancer patients.
Participants will be randomized to receive six sessions of GET or Individual Supportive Therapy (ISP) delivered over eight weeks. In addition to indicators of intervention feasibility, the investigators will measure primary (depressive and anxiety symptoms) and secondary (emotion regulation and goal navigation skills, career confusion) psychological outcomes prior to (T0), immediately after (T1) and twelve weeks after intervention at T2. Additionally, identified biomarkers will be measured at baseline and at T2.
Study Overview
Status
Conditions
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Michael A Hoyt, PhD
- Phone Number: 949-824-9937
- Email: mahoyt@uci.edu
Study Locations
-
-
California
-
Irvine, California, United States, 92697-3957
- Recruiting
- University of California, Irvine
-
Contact:
- Michael A Hoyt, PhD
- Phone Number: 949-824-9937
- Email: mahoyt@uci.edu
-
-
New York
-
New York, New York, United States, 10017
- Recruiting
- Memorial Sloan Kettering Cancer Center
-
Contact:
- Attending Psychologist
- Email: nelsonc@mskcc.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- between the ages of 18 and 39 years at the time of consent
- confirmed diagnosis of testis cancer (any stage)
- completed chemotherapy for testis cancer within 2 years prior to consent
- fluency in English (per self-report)
- sub-optimal self-regulation as evidenced by a score of 1.8 or below on the Goal Navigation Scale or a score of 4 or greater on the Distress Thermometer (DT)
Exclusion Criteria:
- lifetime history of bipolar disorder, schizophrenia, schizoaffective disorder (per self-report)
- active suicide plan
- disorder that compromises comprehension of assessments or informed consent information
- self-reported medical condition or medication use known to confound measures of systemic inflammation
- daily smoking
Study Plan
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Goal Focused Emotion-Regulation Therapy (GET)
GET is a 6-session intervention delivered over 8 weeks to enhance self-regulation through improved goal navigation skills, improved sense of meaning and purpose, and better ability to regulate specific emotional responses.
GET has an emphasis on goal navigation skill building.
This includes work on goal setting with a focus on assessing progress toward achieving specific, realistic, and measurable goals.
Emotion regulation components include basic cognitive restructuring skills, cognitive distancing, and coping efficacy skills (matching the correct coping skill to specific circumstances).
|
Six sessions delivered individually over 8 weeks
|
ACTIVE_COMPARATOR: Individual Supportive Psychotherapy (ISP)
ISP includes 6-sessions of individual supportive psychotherapy and includes components of genuineness, unconditional positive regard, and empathic understanding through reassurance, explanation, guidance, suggestion, encouragement, affecting changes in patient's environment, and permission for catharsis.
ISP emphasizes maintaining focus on the cancer experience, supporting participants in the "here and now," fostering expression of emotion and discussion of difficult topics, and creating a sense of being understood.
|
Six sessions delivered individually over 8 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Hospital Anxiety and Depression Scale (HADS)
Time Frame: Change from Baseline (T0) at 12-weeks Post-Intervention (T2)
|
The HADS was developed to assess anxiety and depression in medical patients.
It purposefully excluded somatic symptoms (e.g., sleep disturbance) to reduce confounding psychological symptoms with disease or treatment.
The HADS has become a "benchmark" measure of anxiety and depression among diverse clinical and nonclinical hospital populations, including individuals diagnosed with cancer.
The HADS is a 14-item self-administered questionnaire, with 7 items assigned to each the HADS-Anxiety and HADS-Depression subscales.
Each item is rated on a 4-point response scale (from 0 to 3).
Subscale scores are typically categorized to indicate the level of anxiety or depression experienced where scores of less than 8 are categorized as normal, scores of 8-10 as borderline, and scores of 11-21 as clinical.
A number of psychometric studies have established the scale's strengths, including its brevity, reliability, and validity and availability of comparison scores across different populations.
|
Change from Baseline (T0) at 12-weeks Post-Intervention (T2)
|
Change in Systemic Pro-inflammatory Cytokine Levels (IL-6, IL-1ra, CRP, sTNFαRII)
Time Frame: Change from Baseline (T0) at intrervention completion, an average of 8 weeks
|
The investigators will focus on four biomarkers, IIL-6, IL-1ra, CRP, sTNFαRII, that indicate systemic inflammation and are associated with distress symptoms and emotion regulation.
Levels will be assessed from plasma.
Cytokine levels will be determined by immunosorbent assay (ELISA) according to assay manufacturer's protocols.
All samples will be run in duplicate, and assays will be repeated on two separate days; intra-assay and interassay mean levels will be used in all analyses.
|
Change from Baseline (T0) at intrervention completion, an average of 8 weeks
|
Change in Salivary Diurnal Cortisol Slope and Daily Output
Time Frame: Change from Baseline (T0) at intrervention completion, an average of 8 weeks
|
Diurnal rhythm in salivary cortisol will be measured over three days at each assessment.
Participants will collect saliva samples in their natural environment upon awakening, 30 minutes later, 8 hours later, and at bedtime.
Participants will complete a diary to assess relevant health behaviors (e.g., caffeine, tobacco, alcohol consumption; physical activity, sleep) as well as daily stress.
They will be instructed to avoid brushing their teeth, eating, or drinking within 20 minutes before sampling.
Participants will keep samples refrigerated prior to returning them to the research laboratory and returned salivettes will be stored in a -20-degree Celsius freezer until analyzed.
After data collection is complete, salivary cortisol will be analyzed with a time-resolved fluorescence immunoassay at the IISBR laboratory at UC Irvine.
Several indices will be computed including diurnal slope, area under the daily curve, cortisol awakening response, and total daily cortisol output.
|
Change from Baseline (T0) at intrervention completion, an average of 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Emotion Regulation Questionnaire (ERQ) Scale Scores
Time Frame: Change from Baseline (T0) at 12-weeks Post-Intervention (T2)
|
Emotion regulation skills will be measured by the Emotion Regulation Questionnaire (ERQ).
The ERQ is a widely used 10-item scale designed to measure respondents' tendency to regulate their emotions in two ways: (1) Cognitive Reappraisal and (2) Expressive Suppression.
Respondents answer each item on a 7-point Likert-type scale ranging from 1 (strongly disagree) to 7 (strongly agree).
The ERQ is widely used in the context of clinical treatment trials and has well established validity, reliability, and factor structure (Goldin, Manber-Ball, Werner, Heimberg, & Gross, 2009; Gross & John, 2003).
|
Change from Baseline (T0) at 12-weeks Post-Intervention (T2)
|
Change in Cancer Assessment for Young Adults (CAYA-T) - Goal Navigation Score
Time Frame: Change from Baseline (T0) at 12-weeks Post-Intervention (T2)
|
Goal navigation capacity includes elements of goal setting, goal clarification, goal adjustment, and goal initiation.
It will be measured by the Goal Navigation subscale of the Cancer Assessment for Young Adults -Testicular (CAYA-T) (Hoyt et al., 2013).
The scale is composed of five items (e.g., "I am able to identify goals in my life", "I know what steps to take to make progress toward my goals", and "I am able to redirect my energy when I feel my life isn't going in the right direction").
Participants indicate how often each item is true of them over the past 7 days on a 3-point response scale ranging from 0 (None of the time) to 2 (Much or most of the time).
Criterion, construct, and procedural validity have been established with young adult testicular cancer survivors.
|
Change from Baseline (T0) at 12-weeks Post-Intervention (T2)
|
Change in Career Thoughts Inventory (CTI) Global Score
Time Frame: Change from Baseline (T0) at 12-weeks Post-Intervention (T2)
|
The CTI (Sampson et al., 1996) is a 48-item self-administered instrument that measures an individual's level of dysfunctional thinking in career decision-making and career problem-solving.
The CTI is normed on adults and broadly used in the context of I/O Psychology.
Items are rated on a 4-point Likert scale ranging from 0 (strongly disagree) to 3 (strongly agree).
CTI total score provides information about an individual's overall level of dysfunctional career thoughts, However, the CTI has three subscales: Decision-Making Confusion (difficulties with initiating or sustaining a career choice), Commitment Anxiety (difficulties with making a commitment to a career choice), and External Conflict (difficulties with balancing one's ideas with the ideas from others).
The CTI has sound evidence for its content, construct, and criterion-related validity (Peila-Shuster & Feller, 2013; Sampson et al., 1996).
|
Change from Baseline (T0) at 12-weeks Post-Intervention (T2)
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2018-4676
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Testis Cancer
-
Martin Blomberg JensenCompleted
-
Odense University HospitalCompleted
-
McMaster UniversityMcMaster Surgical AssociatesCompletedLow-lying Unilateral Palpable Undescended TestisCanada
-
Second Affiliated Hospital of Guangzhou Medical...RecruitingStage IV Ovarian Cancer | Endometrial Cancer Recurrent | Testis Cancer, Refractory | CAR NKChina
-
Sultan Qaboos UniversityRecruitingAnalgesia | Varicocele | Hydrocele | Inguinal Surgery | Undescended Testes | Torsion Testis | Ilioinguinal Nerve BlockOman
-
Nasser HannaCompletedTestis Cancer | Testicular Cancer | Germ Cell TumorUnited States
-
University of Texas Southwestern Medical CenterActive, not recruitingTesticular Germ Cell Tumor | Testicular Neoplasms | Testicular Diseases | Testis Cancer | Testicular Cancer | Germ Cell Tumor | Testicular Yolk Sac Tumor | Testicular Choriocarcinoma | Germ Cell Tumor of Testis | Germ Cell Tumor, Testicular, Childhood | Germ Cell Cancer Metastatic | Germ Cell Neoplasm of Retroperitoneum and other conditionsUnited States
-
St. Luke's Medical Center, PhilippinesThe Hospital for Sick ChildrenCompletedCryptorchidism | Undescended TestisPhilippines
-
Medical Center AlkmaarUnknown
-
Medical Center AlkmaarCompletedUndescended TestisNetherlands
Clinical Trials on Goal-Focused Emotion Regulation Therapy (GET)
-
University of California, IrvineNational Cancer Institute (NCI); Memorial Sloan Kettering Cancer CenterRecruitingTesticular CancerUnited States
-
University of California, IrvineNot yet recruiting
-
Douglas MenninWeill Medical College of Cornell University; Kent State UniversityCompletedGeneralized Anxiety Disorder | Depression, Anxiety | Anxiety Disorders and Symptoms | Emotional DysfunctionUnited States
-
Teachers College, Columbia UniversityRecruitingDepression | Anxiety | Distress, Emotional | Rumination | Self-Criticism | WorryUnited States
-
Teachers College, Columbia UniversityUniversity of MichiganActive, not recruitingDepression | Anxiety | Distress, Emotional | Emotional DysfunctionUnited States
-
University of AarhusCompletedAnxiety DepressionDenmark
-
Leiden UniversityRadboud University Medical Center; ZonMw: The Netherlands Organisation for... and other collaboratorsCompletedPost Traumatic Stress DisorderNetherlands
-
Karolinska InstitutetCompletedBorderline Personality Disorder | Non-suicidal Self-injury (NSSI)Sweden
-
University of TorontoRecruiting
-
Islamic Azad University, Najafabad BranchCompletedFunctional Gastrointestinal Disorders